Mechanisms of cyclooxygenase-2 inhibition and cardiovascular side effects - The plot thickens

Cancer Prevention Research

Volumn 2, Issue 4, 2009, Pages 288-290

  Marnett, Lawrence J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; IBUPROFEN; MONTELUKAST; PROSTAGLANDIN; ROFECOXIB; SULINDAC; THROMBOXANE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ACUTE HEART INFARCTION; ASTHMA; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; DRUG EXCRETION; DRUG URINE LEVEL; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; LUNG CANCER; MASS SPECTROMETRY; NONHUMAN; POLYP; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; METABOLISM; NOTE;

ANIMALS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG TOXICITY; HUMANS;

EID: 67549120064     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0033     Document Type: Review

References (20)

1. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884
2. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-1682
3. Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylomithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled double-blind trial. Cancer Prev Res 2008;1:32-38
4. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102 (Pubitemid 40365350)
5. Marnett LJ. The COXIB experience: a look in the rear-view mirror. Annu Rev Pharmacol Toxicol 2009;49:265-290
6. Bertagnolli M, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib trial. Cancer Prev Res 2009;2:310-321
7. DuBois RN. New, long-term insights from the adenoma prevention with celecoxib trial on a promising but troubled class of drugs. Cancer Prev Res 2009;2:285-287
8. Gross ND, Boyle JO, Morrow JD, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005;11:6087-6093
9. 4 are increased in the urine of smokers: Evidence that celecoxib shunts arachidonic acid into 5-lipoxygenase pathway. Cancer Prev Res 2009;2:322-329
10. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005 (Pubitemid 29233213)
11. Taha R, Olivenstein R, Utsumi T, et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:636-640 (Pubitemid 30129478)
12. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 2003;100:1238-1243 (Pubitemid 36183986)
13. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37. (Pubitemid 38032181)
14. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245-2256
15. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38:68-74. (Pubitemid 43011884)
16. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-239 (Pubitemid 38282747)
17. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992;85:230-236
18. Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis 1993;4:899-904.
19. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277 (Pubitemid 29036089)
20. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005;26:827-834